Curaleaf has beaten EPS estimates in each of its last four reported quarters. Its next earnings report, due after the market closes on November 3, will put that streak to the test. Analysts expect a loss, and the company still needs to turn sales growth into stronger profits.
Curaleaf Holdings Inc. (TSX: CURA) is set to report results for the quarter ended September 30, 2026. One analyst expects a loss of US$0.21 per share and revenue of US$345.6 million, up 7.9% from a year earlier. The EPS estimate hasn’t changed in 30 days, though one analyst lowered their estimate and none raised theirs. Curaleaf has beaten estimates in each of its past four reported quarters. This time, investors will be watching to see whether sales growth and operating improvements can hold up amid pricing pressure and high expenses. The latest available close for Canadian investors is C$12.13. See the Curaleaf stock page for company details and market data.
Recent earnings trend
Curaleaf Holdings Inc.
CURA.TO
CURA.TO
Curaleaf Holdings Inc.
WealthAwesomeMarket cap
$3.21B
52W high
$20.93
52W low
$7.77
1W change
+6.59%
Beta
1.60
Analyst Price Targets
Based on analyst covering CURA · as of Oct 30, 2026
Wall Street analysts forecast CURA stock price to rise 49.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$18.11
+49.3% Upside
Previously C$18.12 on Oct 29, 2026
Current Price
C$12.13
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CURA's historical volatility
30-Day Vol
58.8%
Annualized
90-Day Vol
57.1%
Annualized
Trend (90d)
-17.3%
Annualized drift
90d Mean
C$11.40
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$11.88 | C$9.70 – C$14.55 |
| 60 trading days | C$11.64 | C$8.74 – C$15.51 |
| 90 trading days | C$11.40 | C$8.03 – C$16.20 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 4 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-03 | — | -0.1500 | — |
| 2026-06-30 | 2026-08-05 | 0.0700 | -0.2400 | +129.2% |
| 2026-03-31 | 2026-05-04 | 0.2900 | -0.2700 | +207.4% |
| 2025-12-31 | 2026-02-26 | -0.0500 | -0.0900 | +44.4% |
| 2025-09-30 | 2025-11-04 | -0.1900 | -0.2400 | +20.8% |
| 2025-06-30 | 2025-08-06 | -0.1900 | -0.2100 | +9.5% |
Investor takeaway: Curaleaf’s recent EPS record and expected revenue growth are encouraging, but they don’t guarantee another beat. The company needs to show that sales gains are leading to lasting margin improvement and stronger profits. With only one analyst contributing to the consensus, the estimate offers a limited view of expectations.
US$0.21 loss per share
That’s the one-analyst EPS estimate for the quarter ended September 30, compared with a loss of US$0.19 a year earlier. The estimate hasn’t changed in the past 30 days, but analyst coverage is limited. Curaleaf’s four-quarter beat streak is useful context, not a promise of another surprise.
Bull case
Curaleaf beat EPS estimates in each of its last four reported quarters. Actual EPS ranged from a loss of US$0.05 to earnings of US$0.29, while analysts had expected a loss each time. The revenue estimate points to 7.9% growth from a year earlier. Recent company updates also cite stronger wholesale demand, a return to growth in the domestic business, and rising international revenue.
In the second quarter, gross margin reached 50%, up 70 basis points from a year earlier. Management also targeted US$35 million to US$40 million in SG&A savings over the next 12 months. If sales momentum continues and cost controls deliver, the results could support the view that the business is improving.
Bear case
Four quarters of EPS beats don’t solve Curaleaf’s profitability problem. Its reported trailing-twelve-month EPS is -US$0.19, and its profit margin is -2.63%. Analysts still expect a loss, with estimated EPS down 10.2% from the year-ago loss of US$0.19.
Recent company updates point to an approximately 4% drop in average unit retail prices and a 120-basis-point decline in adjusted EBITDA margin from a year earlier, despite higher gross margin. Curaleaf is also pursuing a contested takeover bid for Aurora Cannabis, adding deal uncertainty to the operating issues investors will be watching.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
